RxDoctor Payments Data

Farah Aljuboory, MD

Hospitalist · Amarillo, TXNPI 1982043899

Payments from drug & device makers

$724in general payments, 2019–2025

Across 33 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$205
  • Boehringer Ingelheim$134
  • Pfizer$91
  • Ferring Pharmaceuticals Inc.$62
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$46
  • AstraZeneca$36
  • plus $150 from 6 others

What the payments were for

  • Food & beverage$724100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$724 in reported general payments places this provider in the 85th percentile of 1,284 hospitalist providers in Texas.

See all hospitalist providers in Texas

Medicare billing

Part B allowed, 2024
$111,941
Medicare patients
356
Services billed
1,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$12,617
EntrestoSacubitril/Valsartan11$6,985
Cefpodoxime Proxetil32$1,006
Midodrine Hcl11$352
Nitroglycerin14$337
Atorvastatin Calcium41$289
Amiodarone Hcl12$289
Potassium Chloride28$276
Pantoprazole Sodium28$250
Donepezil Hcl11$159
Hydralazine Hcl13$145
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav18$141
Metoprolol Succinate21$130
Clonidine Hcl12$124
Levothyroxine Sodium29$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$12,61723 claims
NovartisEntresto$21$6,98511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 hospitalist providers in Texas.

Other hospitalist in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →